PDCD1 and hepatocellular carcinoma: A notable area of exploration is its integration with immunotherapeutic agents, exemplified by studies investigating the synergy between radiation therapy, regorafenib, and PD-1 inhibitors, unveiling promising strides in therapeutic efficacy and manageable toxicity profiles in advanced HCC stages [34].